Try the modernized beta website. Learn more about the modernization effort.
Working… Menu

Effect of Eplerenone on Endothelial Function in Metabolic Syndrome (MetSyn)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT01319344
Recruitment Status : Completed
First Posted : March 21, 2011
Last Update Posted : April 17, 2013
Information provided by (Responsible Party):
Roland E. Schmieder, University of Erlangen-Nürnberg Medical School

Brief Summary:

Patients with the metabolic syndrome (MetSyn) are at increased risk for cardiovascular mortality and morbidity.This increased cardiovascular risk is attributed to metabolic dysregulations like impaired glucose tolerance or diabetes mellitus and dyslipidemia, abdominal obesity and arterial hypertension, which promote oxidative stress and inflammation with consecutive endothelial dysfunction causing an atherogenic environment.

Aldosterone promoted end organ damage is mainly found in the cardiovascular system and the kidney. Inflammation and activation of different factors promotes fibroblast growth and matrix production resulting in myocardial fibrosis, vascular remodelling and renal fibrosis.

MetSyn and aldosterone are cardiovascular risk factors and it is of crucial importance to note that there is a connection between MetSyn and aldosterone. Other cross sectional studies show a direct correlation of aldosterone levels and impaired glucose metabolism in patients with and without the MetSyn. Taken together, aldosterone influences essential parameters of the MetSyn. Coincidentally parameters of the MetSyn are stimulus for an increased aldosterone synthesis, i.e. visceral adipocytes.

In large scale clinical trials - RALES, EPHESUS, 4E - inhibition of MR has proven to be beneficial in patients with congestive heart failure and post myocardial infarction and this result has been confirmed for diabetic patients, who are known to have an increased cardiovascular risk.

There is only very limited data on the impact of MR inhibition on metabolic, endocrine, and inflammatory parameters in patients with MetSyn, who have not yet suffered from cardiovascular events.

Condition or disease Intervention/treatment Phase
Metabolic Syndrome Endothelial Dysfunction Drug: Eplerenone Phase 3

Show Show detailed description

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 42 participants
Allocation: N/A
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Prevention
Official Title: Prospective and Open Label Study With Blind End Point Evaluation on the Effect of Mineralocorticoid Receptor Inhibition on Endothelial Function of the Micro- and Macrovasculature in Patients With Metabolic Syndrome
Study Start Date : September 2010
Actual Primary Completion Date : December 2012
Actual Study Completion Date : April 2013

Resource links provided by the National Library of Medicine

Drug Information available for: Eplerenone

Arm Intervention/treatment
Experimental: Eplerenone Drug: Eplerenone
25 mg o.d. per os
Other Name: Inspra

Primary Outcome Measures :
  1. Change of basal nitric oxide activity as assessed by change of retinal capillary flow (measured by Scanning Laser Doppler Flowmetry) [ Time Frame: Ten weeks ]

Secondary Outcome Measures :
  1. Changes of distensibility of the carotid artery. [ Time Frame: Ten weeks ]
  2. Change of flow mediated dilation of the brachial artery. [ Time Frame: Ten weeks ]

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   Male
Accepts Healthy Volunteers:   No
  • Male patients aged > 18 years with mild uncomplicated primary arterial hypertension with a mean sitting SBP ≥ 130 mmHg or DBP ≥ 85 mmHg or treated hypertension and at least 2 of the following traits of the metabolic syndrome (ATP III criteria):

    • abdominal obesity (abdominal girth ≥ 102 cm in males),
    • triglyceride level ≥ 150 mg/dL or treatment for elevated triglyzerides,
    • HDL < 40 mg/dL or treatment for low HDL
    • fasting blood glucose ≥ 100 mg/dL and ≤ 126 mg/dl.
    • Written informed consent
    • Agreement to attend all study visits as planned in the protocol

Exclusion Criteria:

  • Patients with or without antihypertensive therapy and mean blood pressure > 160/100 mmHg
  • Patients with secondary hypertension
  • Patients with one antihypertensive agent maximally dosed or two (or less) agents with half (or less) of maximum approved dose
  • Patients with diabetes mellitus type 1 or type 2
  • Smokers and ex-smokers < 1 year
  • Female patients (to prevent effects of changes in endothelial function attributable to the menstrual cycle)
  • Patients with sick sinus syndrome
  • Patients with higher degree of sinoatrial or atrioventricular block (II-III)
  • Patients with bradycardia (< 50 beats/min)
  • Patients with malignant arrhythmias
  • Patients with known cardiovascular, disease
  • Patients with known cerebrovacular disease
  • Patients with peripheral occlusive artery disease
  • Patients with history of epilepsy
  • Patients with severe hepatic disease (serum GOT, GPT, gamma-GT, AP, bilirubin > 300 of uppper normal range)
  • Patients with renal disease defined by eGFR < 60 ml/min/1,73m2
  • Patients with history of malignant disease within the last 2 years
  • Patients with history of depression
  • Patients with drug or alcohol abuse
  • Use of any investigational drug within 28 days before study entry
  • Known allergy or a known intolerance to the study drug
  • Likelihood of requiring treatment during the study period with drugs not permitted by the clinical study protocol, especially likelihood of the need for additional antihypertensive medication
  • Serious disorders which may limit the ability to evaluate the efficacy or safety of the test drug(s), including cerebrovascular, cardiovascular, renal, respiratory, hepatic, gastrointestinal, endocrine or metabolic, haematological or oncological, neurological and psychiatric diseases
  • Subject is the investigator or any subinvestigator, research assistant, pharmacist, study coordinator, other staff or relative thereof directly involved in the conduct of the protocol
  • Mental conditions rendering the subject unable to understand the nature, scope and possible consequences of the study
  • Subject unlikely to comply with protocol, e.g. uncooperative attitude, inability to return for follow-up visits and unlikelihood of completing the study

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT01319344

Layout table for location information
Clinical Research Unit, Department of Nephrology and Hypertension, University of Erlangen-Nurnberg
Erlangen, Germany, 91054
Clinical Research Unit, Department of Nephrology and Hypertension, University of Erlangen-Nürnberg
Nürnberg, Germany, 90471
Sponsors and Collaborators
University of Erlangen-Nürnberg Medical School
Layout table for investigator information
Principal Investigator: Roland E Schmieder, Prof University of Erlangen-Nurnberg
Publications automatically indexed to this study by Identifier (NCT Number):
Layout table for additonal information
Responsible Party: Roland E. Schmieder, Prof. Dr. med., University of Erlangen-Nürnberg Medical School Identifier: NCT01319344    
Other Study ID Numbers: MSyn-2010
First Posted: March 21, 2011    Key Record Dates
Last Update Posted: April 17, 2013
Last Verified: April 2013
Additional relevant MeSH terms:
Layout table for MeSH terms
Metabolic Syndrome
Pathologic Processes
Insulin Resistance
Glucose Metabolism Disorders
Metabolic Diseases
Mineralocorticoid Receptor Antagonists
Hormone Antagonists
Hormones, Hormone Substitutes, and Hormone Antagonists
Physiological Effects of Drugs
Diuretics, Potassium Sparing
Natriuretic Agents
Antihypertensive Agents